Peptron

펩트론 · 087010

Health Care Pharmaceuticals · KOSDAQ

Large-cap

Market cap US$4.6B (₩6.3T)

Overview

Peptron develops medicines that stay active in the body for longer than conventional drugs, using peptide engineering and sustained-release technology to reduce how often patients need a dose.

It operates in the drug-development and pharmaceutical manufacturing space, targeting both clinical-stage and commercial products. Listed on KOSDAQ, Korea's tech and small-cap board, the company has built its own GMP-certified large-scale production facility capable of supplying both clinical-trial materials and commercially launched drugs.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$4.1M

▲ +78.8% YoY

Operating profit · FY2025

−US$15.4M

Loss widened

Net income · FY2025

−US$10M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$2.4M(₩3.3B)	US$2.3M(₩3.2B)	US$4.1M(₩5.6B)
Operating profit	−US$11.5M(−₩15.9B)	−US$12M(−₩16.5B)	−US$15.4M(−₩21.3B)
Net income	−US$11.5M(−₩15.9B)	−US$16M(−₩22B)	−US$10M(−₩13.8B)

Revenue

FY2023US$2.4M
FY2024US$2.3M
FY2025US$4.1M

Operating profit

FY2023−US$11.5M
FY2024−US$12M
FY2025−US$15.4M

Net income

FY2023−US$11.5M
FY2024−US$16M
FY2025−US$10M

Key ratios (FY2025)

ROE

-9.7%

Debt/Eq

26.0%

Op. margin

-377.3%

Net margin

-245.3%

Rev. YoY

▲ +78.8%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?